Anlon Healthcare Limited disclosed that its Chairman & Managing Director, Mr. Punitkumar Rasadia, participated in an interview with Money TV on June 30, 2026, to discuss the company's strategic direction and operational progress. The interaction aimed to provide stakeholders with insights into the company's current business performance and future outlook without disclosing any unpublished price sensitive information (UPSI).

During the interview, Mr. Rasadia provided a comprehensive overview of the company's business performance and the prevailing industry outlook. He elaborated on the current market conditions and shared recent operational updates, highlighting the company's adaptability to the dynamic healthcare sector.

The discussion also focused on the company's growth strategy and future plans. Mr. Rasadia outlined the roadmap for expansion, including potential capital expenditure and capacity expansion initiatives. He addressed topics concerning acquisition and disinvestment strategies, indicating the management's proactive approach to scaling operations.

Financial performance guidance was a key component of the interview, offering shareholders a perspective on the company's fiscal expectations. The management emphasized that all information shared during the session was already available in the public domain, ensuring compliance with regulatory standards.

The interview is accessible for viewing on the Money TV website and YouTube. The company confirmed that the interaction was conducted in adherence to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Anlon Healthcare Ltd approved the incorporation of two new subsidiaries on July 1, 2026, to expand its presence in the pharmaceuticals sector. The Board of Directors sanctioned the creation of Anlon Medicare Private Limited and Anlon Biologics Private Limited, alongside a proposal to rename an existing subsidiary. The company will invest an aggregate initial capital of up to ₹17.5 lakh to establish these entities, aiming to leverage growth opportunities in surgical implants and biological products.

The Board meeting, held at the company's registered office in Rajkot, approved the incorporation under Sections 2(87), 186, and other applicable provisions of the Companies Act, 2013. The decision aligns with the company's strategy to complement and expand its existing business in the pain management segment and other high-growth areas. Both subsidiaries will be incorporated in India, subject to approvals from the Registrar of Companies.

Anlon Healthcare will subscribe to the equity share capital of the proposed subsidiaries via cash consideration. For Anlon Medicare Private Limited, the company will subscribe to 55% of the equity share capital by investing up to ₹1,100,000 for 1,10,000 equity shares of ₹10 each. This entity will focus on manufacturing surgical implants and medical devices.

In the case of Anlon Biologics Private Limited, the company will acquire a 65% stake by investing up to ₹650,000 for 65,000 equity shares of ₹10 each. This subsidiary is being established to develop and manufacture peptides, biosimilars, and biological compositions. The company anticipates significant growth in this sector and aims to position itself to benefit from expanding opportunities.

Investment and Shareholding Details

The following table outlines the investment structure for the two newly approved subsidiaries:

Additionally, the Board approved changing the name of an existing subsidiary, Remember India Health Links Private Limited, to Anlon Medicos Private Limited. This change is subject to approval from the Ministry of Corporate Affairs. The intimation was submitted to the BSE Limited and the National Stock Exchange of India under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.